NGF Treatment for Patients With Neuropathic Corneal Pain

Summary

This prospective, single center, interventional, open-label, single arm, non-randomized trial seeks to investigate the efficacy of Oxervate® (cenergermin 0.002% eye drops) on ameliorating the signs and symptoms of neuropathic corneal pain (NCP). The study aims to enroll 28 subjects with NCP. All patients will be evaluated for clinical symptoms and signs of NCP, corneal staining and nerve regeneration (by IVCM) at Baseline (Visit 2) through the end of study (16 weeks post treatment).

Timeline

Start

2022-11-01

Primary completion

2023-12-01

Completion

2023-12-01

Outcome

Outcome not reported

Stopped (Business): “Funding of study was withdrawn”

Drugs

Indications